|MDS in the Lower-risk Patient: The Current Treatment Algorithm|
Hetty E. Carraway, MD, MBA, FACP
|Release Date: April 16, 2020|
Expiration Date: April 15, 2021
How is low-risk MDS identified and treated today in your practice? Read a recent interview with Dr. Hetty Carraway where she discusses lower-risk myelodysplastic syndromes (MDS) defined by the International Prognostic Scoring System (IPSS) and an updated “revised” version (IPSS-R). In this discussion, Dr. Carraway provides readers with an overview of current standards of care and where the newly approved agent luspatercept fits in the treatment paradigm.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|